Can I Take Vitamin B12 with Methimazole (Tapazole)?

Methimazole (brand name Tapazole) is a thionamide antithyroid medication, FDA-approved for hyperthyroidism, including Graves disease. Vitamin B12 (cobalamin) is a water-soluble vitamin available as cyanocobalamin, methylcobalamin, hydroxocobalamin, or adenosylcobalamin, sold over the counter as a standalone supplement, in B-complex products, and in multivitamins.

Methimazole has no recognized pharmacokinetic interaction with vitamin B12. The drug does not alter intrinsic factor secretion, gastric acid output, or the ileal receptor system that cobalamin depends on for absorption, so there is no pharmacologic reason to separate doses or avoid taking them together. Vitamin B12 deficiency is, however, reported more often in people with Graves disease and other autoimmune thyroid conditions than in the general population, most plausibly because autoimmune atrophic gastritis and pernicious anemia share genetic and immunologic risk factors with autoimmune thyroid disease, not because methimazole itself depletes the vitamin. That distinction is the reason B12 status is worth checking in this population even though co-administration itself carries no known safety signal.

The short answer: no direct interaction, but a real reason to monitor

Methimazole is absorbed in the gastrointestinal tract, metabolized hepatically, and excreted renally. It blocks thyroid peroxidase, the enzyme responsible for iodide oxidation and iodotyrosine coupling in thyroid hormone synthesis. None of this touches the intrinsic-factor-dependent absorption pathway that vitamin B12 relies on, and the FDA's drug interaction resources do not list a methimazole-cobalamin interaction (FDA drug interaction database).

That clean pharmacologic picture is separate from the epidemiologic one. Graves disease and Hashimoto thyroiditis are autoimmune conditions, and autoimmune disease clusters: people with one organ-specific autoimmune diagnosis are more likely than the general population to have another, including autoimmune atrophic gastritis and pernicious anemia, the two leading causes of clinically significant B12 deficiency in adults (NIH Office of Dietary Supplements, Vitamin B12 fact sheet for health professionals). That clustering, not the drug, is the reason clinicians check B12 in this group.

What "no interaction" actually rules out

A direct drug-supplement interaction means one substance changes the absorption, distribution, metabolism, or excretion of the other. Methimazole does not affect gastric acid secretion, intrinsic factor production, or the cubilin-amnionless receptor complex in the ileum that mediates B12 uptake. Vitamin B12 does not affect methimazole's absorption or hepatic clearance, and it does not alter thyroid function test results (TSH, free T4, free T3), so taking a B12 supplement does not need to be timed around thyroid lab draws.

Why the autoimmune overlap still matters clinically

Anti-thyroid peroxidase antibodies, common in Graves disease, frequently coexist with anti-parietal cell antibodies, which mark ongoing destruction of the gastric cells that make intrinsic factor. A single published case report describes a patient treated for Graves disease with methimazole who was found to have severe vitamin D deficiency and hypocalcemia, illustrating that clinicians managing methimazole-treated Graves patients sometimes uncover unrelated micronutrient deficiencies during workup (Case report, Hypocalcemia with severe vitamin D deficiency following treatment for Graves disease with methimazole). That report concerns vitamin D and calcium, not B12, and a single case cannot establish a rate or a mechanism specific to B12; it is included here only as evidence that nutrient status checks in this population have precedent, not as direct proof of a B12 finding.

Methimazole pharmacology relevant to supplement use

Methimazole reaches peak plasma concentration within a few hours of an oral dose and is cleared primarily through hepatic metabolism, with a relatively short half-life that is why active hyperthyroidism is often dosed more than once daily. Its clinically important drug interactions involve anticoagulants (warfarin effect can change as thyroid status normalizes and clotting factor synthesis shifts), beta-blockers (dose often needs adjustment as heart rate normalizes), and drugs like digoxin whose clearance is sensitive to thyroid status. None of these mechanisms involve cobalamin, and specific numeric interaction magnitudes should be confirmed with a pharmacist or the current FDA label rather than assumed from this page.

B12 deficiency in autoimmune thyroid disease: what is established and what is not

Established: Autoimmune thyroid disease and pernicious anemia/autoimmune gastritis share autoimmune risk, and screening guidance for autoimmune thyroid patients generally recommends clinician awareness of, and screening for, other autoimmune conditions when clinically indicated.

Plausible but not settled on this page's evidence: Specific prevalence figures (for example, what percentage of Graves patients have measurable B12 deficiency, or what percentage eventually develop pernicious anemia) are reported in the literature, but the sourcing behind those numbers in earlier versions of this article could not be verified against the cited papers. Readers and clinicians should treat any precise percentage as needing confirmation from a current, verifiable primary source rather than repeating it as fact.

Not established from available evidence: That methimazole itself causes, accelerates, or worsens B12 deficiency through any pharmacologic mechanism.

Neurological consequences of B12 deficiency

Vitamin B12 deficiency can cause peripheral neuropathy, gait instability, cognitive slowing, glossitis, and, in severe or prolonged cases, subacute combined degeneration of the spinal cord, along with megaloblastic anemia. Because untreated hyperthyroidism itself produces tremor, anxiety, and paresthesias, B12 deficiency symptoms can be masked by, or mistaken for, incompletely controlled thyroid disease. A serum B12 level is an inexpensive way to resolve that ambiguity when neurological symptoms persist after thyroid hormone levels normalize on methimazole.

Evidence-status interaction assessment

Practical use: timing, dosing, and monitoring

No dose-separation window is required between methimazole and vitamin B12; they can be taken at the same time, with or without food.

Choosing a B12 form. For someone with normal intrinsic factor function, oral cyanocobalamin or methylcobalamin in the range commonly recommended by the NIH Office of Dietary Supplements is generally adequate for correcting mild insufficiency. For confirmed pernicious anemia with absent intrinsic factor, intramuscular or high-dose oral regimens are both used in practice; the comparative effectiveness of oral versus injectable routes for this specific indication should be confirmed with a clinician and current guideline rather than assumed from general dosing tables.

Reference dosing points (general, not individualized advice):

• Adult dietary reference intake for B12: roughly 2.4 mcg/day, per the Institute of Medicine's Dietary Reference Intakes report (NCBI Bookshelf, Dietary Reference Intakes for B12 and related vitamins)
• Standard multivitamin B12 content is typically in the range of a few to a few dozen micrograms per tablet, far below therapeutic repletion doses, and will not interfere with methimazole or thyroid testing
• Methimazole dosing (induction and maintenance) should follow the current FDA label and prescriber guidance; this page does not provide individualized dosing instructions

A reasonable monitoring pattern, subject to a prescriber's judgment: check serum B12 at the time methimazole is started, then periodically thereafter, with more frequent rechecking if the level is low-normal, if anti-parietal cell or anti-intrinsic factor antibodies are positive, or if the patient also takes metformin. Values consistent with deficiency should prompt evaluation for the underlying cause, including pernicious anemia, rather than supplementation alone.

Special populations

Older adults. Age-related achlorhydria and a higher background rate of autoimmune atrophic gastritis make B12 monitoring a reasonable priority for older adults on long-term methimazole, though universal screening is not currently recommended by major preventive-care bodies; clinical suspicion should guide testing.

Vegetarians and vegans. Plant-based diets provide minimal preformed B12. A vegan or vegetarian patient starting methimazole already carries a dietary risk factor for deficiency independent of thyroid status, and routine supplementation is a reasonable precaution to discuss with a clinician.

Pregnancy. Methimazole is generally avoided in the first trimester because of a recognized embryopathy risk, with alternatives such as propylthiouracil often preferred during that window per current thyroid management guidance; this is a decision for the treating clinician, not something to self-manage. B12 needs increase modestly during pregnancy, and adequate intake through diet or supplementation is reasonable, but this page does not provide pregnancy-specific dosing.

Renal impairment. B12 is water-soluble and renally excreted; standard supplemental doses generally do not require adjustment in renal disease, though dialysis patients can have additional losses and may need separate monitoring by their nephrology or endocrinology team.

Safety profile of vitamin B12 at supplemental doses

No tolerable upper intake level has been established for vitamin B12 because significant toxicity from high oral doses has not been demonstrated in humans. The main safety concern with injectable B12 is rare hypersensitivity to the formulation, not a toxicity related to the vitamin itself. A transient rise in serum B12 shortly after supplementation is expected and not itself a red flag; persistently very high B12 levels found without supplementation are a separate clinical question (sometimes associated with liver disease or other conditions) and are not addressed by this page.

Red flags that warrant prompt evaluation, not a scheduled recheck

The following findings in someone taking methimazole justify checking B12 status sooner rather than waiting for a routine annual test, and in some cases warrant urgent evaluation:

• Numbness, tingling, or weakness in the hands or feet that persists after thyroid levels have normalized
• New gait instability or balance problems
• A smooth, painful tongue (glossitis) or recurrent mouth ulcers
• Macrocytic anemia found on a routine complete blood count
• Any new or worsening neurological symptom, which should be evaluated urgently rather than attributed automatically to either thyroid disease or B12 status without testing

Evidence boundary

Established: Methimazole has no known pharmacokinetic or pharmacodynamic interaction with vitamin B12; the two can be co-administered without timing restrictions; B12 does not affect thyroid function test results; autoimmune thyroid disease and autoimmune gastric disease (including pernicious anemia) share recognized autoimmune risk.

Plausible but not confirmed here: That B12 deficiency is meaningfully more common in Graves disease specifically than in autoimmune thyroid disease generally, and any exact prevalence figure for that risk.

Not established: Any direct depleting effect of methimazole on B12 status; any benefit of routine B12 supplementation for people without documented deficiency or risk factors; universal screening recommendations from major guideline bodies specific to methimazole users.

If neurological symptoms are severe, rapidly worsening, or accompanied by confusion, loss of bladder or bowel control, or significant weakness, seek urgent medical care rather than waiting for a scheduled lab draw.

Talking to your prescriber

Mentioning a B12 supplement at a visit is useful mainly because it gives the clinician a reason to order a baseline serum B12 and document it as a reference point, not because approval is needed for safety reasons. If a multivitamin or B-complex already contains B12 at standard doses, no change is typically needed. Anyone taking metformin alongside methimazole should flag that combination specifically, since metformin's effect on B12 absorption is a separately documented and more firmly established concern than any effect from methimazole.